Lv7
4910 积分 2022-11-08 加入
Anlotinib plus penpulimab versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma (APOLLO): a randomised, controlled, phase 3 trial
11小时前
已完结
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study
7天前
已完结
Sorafenib plus Doxorubicin versus Sorafenib alone for advanced hepatocellular carcinoma (Soradox trial): final results of a prospective, randomized, open-label, multicenter phase IIB trial
9天前
已完结
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
13天前
已完结
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
1个月前
已完结
Clinical Development of the Anti–CTLA-4 Antibody Tremelimumab
2个月前
已完结
FDA Approval Summary: Tremelimumab in Combination with Durvalumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma
2个月前
已完结
Tremelimumab: First Approval
2个月前
已完结
The colorectal cancer drug market
2个月前
已完结
Association of Anti-TNF with Decreased Survival in Steroid Refractory Ipilimumab and Anti-PD1–Treated Patients in the Dutch Melanoma Treatment Registry
2个月前
已完结
皖公网安备34019202002308
